Advancing Tissue Factor-targeted Therapy for Osteosarcoma via Understanding its Role in the Tumor Microenvironment

• Published in: Current pharmaceutical design Vol. 29; no. 13; p. 1009
• Main Authors: Ichikawa, Jiro, Schoenecker, Jonathan G, Tatsuno, Rikito, Kawasaki, Tomonori, Suzuki-Inoue, Katsue, Haro, Hirotaka
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01-01-2023
• Subjects: Blood Coagulation; Bone Neoplasms - drug therapy; Humans; Osteosarcoma - drug therapy; Osteosarcoma - pathology; Thromboplastin - metabolism; Tumor Microenvironment; heparin; tissue factor; Osteosarcoma; antibody-drug-conjugate; low molecular weight heparin; tumor microenvironment; chemotherapy
• ISSN: 1873-4286
• DOI: 10.2174/1381612829666230413094242

Coagulation activation is associated with cancer progression and morbidity. Recently, mechanisms through which coagulation proteases drive the tumor microenvironment (TME) have been elucidated. This review aims to develop a new strategy dependent on the coagulation system for treating osteosarcoma (OS). We focused on tissue factor (TF), the main initiator of the extrinsic coagulant pathway, as a target for OS treatment. It was found that cell surface-TF, TF-positive extracellular vesicles, and TF-positive circulating tumor cells could drive progression, metastasis, and TME in carcinomas, including OS. Thus, targeting tumor-associated coagulation by focusing on TF, the principle catalyst of the extrinsic pathway, TF is a promising target for OS.